Every material Form 8-K Autonomix Medical, Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its October 29, 2026 annual meeting, Autonomix Medical stockholders approved an increase of 750,000 shares under the 2023 Stock Plan and authorized the board to seek a reverse stock split of between 1-for-2 and 1-for-25. All six director nominees were elected, and Forvis Mazars, LLP was ratified as the independent auditor for the year ending March 31, 2027. The votes give the board flexibility on share count and equity awards, but the filing does not say whether a reverse split will be pursued.
Annual meeting held October 29, 2026; 905,610 shares voted, about 46% of 1,959,938 shares outstanding as of the September 8, 2026 record date.
2023 Stock Plan amended to add 750,000 shares; total issuable under the plan is 750,353 shares.
Reverse split proposal approved with 775,257 votes for and 110,036 against, authority valid until the one-year anniversary of the meeting.
Plan amendment approved with 225,651 votes for and 39,672 against.
Autonomix Medical increased its Board from five to six members and appointed Sandra Kalter, a former Medtronic Vice-President and Chief Regulatory Counsel, as an independent director effective immediately. The filing says she has not been named to any Board committee yet, and the appointment is presented as adding medical device regulatory and industry experience.
Board size increased from five to six members; appointment made September 14, 2026, effective immediately
Kalter served at Medtronic plc in senior roles, most recently as Vice-President and Chief Regulatory Counsel from May 2011 to January 2025
No Board committee appointments at this time; she will join the standard non-employee director compensation program
Press release (Exhibit 99.1) dated September 16, 2026 announces the appointment
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Autonomix Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →